Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€25.69

€25.69

1.220%
0.31
1.220%
€26.96

€26.96

 
31.07.26 / Tradegate WKN: A0M6U7 / Symbol: IVZ / Name: Invesco / Stock / Investment Banking & Investment Services / Mid Cap /
Latest predictions
01.08.26
-
buy
€30.71
29.07.26
4.73%
buy
23.07.26
-1.98%
buy
€27.24
02.07.26
8.72%
buy
24.06.26
13.77%
buy
08.06.26
6.86%
buy
Your prediction

Invesco Ltd. Stock

There is an upward development for Invesco Ltd. compared to yesterday, with an increase of €0.31 (1.220%).
With 21 Buy predictions and not a single Sell prediction Invesco Ltd. is an absolute favorite of our community.
As a result the target price of 26 € shows a slightly positive potential of 1.21% compared to the current price of 25.69 € for Invesco Ltd..
For the coming years our community has positive and negative things to say abot the Invesco Ltd. stock. Criterium "EBIT growth" gathered the most positive votes but regarding "Management" there were negative voices in the community.

Pros and Cons of Invesco Ltd. in the next few years

Pros
?
S********** s********
?
B****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Invesco Ltd. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Invesco Ltd. 1.220% -2.431% 11.260% 39.574% 11.068% 70.584% 24.951%
Federated Investors Inc. -0.960% 3.414% 5.102% 18.664% 13.436% 69.408% 86.594%
Ares Management L.P -0.970% 4.718% 10.184% -34.143% -24.562% 19.718% 82.550%
Affiliated Managers Group 1.270% 4.605% 6.000% 73.770% 29.268% 156.452% 137.313%

sharewise BeanCounterBot AI-generated

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2025-04-29

Invesco Ltd. (IVZ) demonstrates a stable financial position with some positive trends in its latest quarterly report (Q2 2025). Key findings include:

The overall financial trend appears positive, driven by revenue growth and improved profitability.

The company shows improving profitability due to better cost management and revenue growth.

Comments

Invesco (IVZ) was upgraded by Zacks Research from "hold" to "strong-buy".
Ratings data for IVZ provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 4.73%
Target price 30.713
Change
Ends at 29.07.27

Invesco (IVZ) had its price target raised by Royal Bank Of Canada from $33.00 to $35.00. They now have an "outperform" rating on the stock.
Ratings data for IVZ provided by MarketBeat
Show more

Invesco (IVZ) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Ratings data for IVZ provided by MarketBeat
Show more

News

XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?Photo, wide shot, wide-angle lens,  Bank, sunset photo at golden hour, photo by Art Wolfe: https://img.theapi.app/temp/3aa597ca-f944-4a9b-bf8d-3071f3b5a5c9.png
XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?

The State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) provides broad exposure to the S&P 500 healthcare sector, whereas the Invesco Nasdaq Biotechnology ETF (NASDAQ:IBBQ) offers a

XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist?Photo, wide shot, wide-angle lens,  Private equity firm, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Edward Burtynsky: https://img.theapi.app/temp/2b695cca-48cb-4195-802a-e3385fb90ec0.png
XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist?

The State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) offers broad exposure to the S&P 500 healthcare sector at a low cost, whereas the Invesco Biotechnology & Genome ETF (NYSEMKT:PBE)

Invesco Mortgage Capital Q2 Earnings Call HighlightsPhoto, wide shot, wide-angle lens,  Private equity firm, sunset photo at golden hour, photo by Ansel Adams: https://img.midjourneyapi.xyz/temp/11edc0a6-edfc-46d1-baee-abd4f510abd1.png
Invesco Mortgage Capital Q2 Earnings Call Highlights

Key Points